apremilast (otezla) Report issue

Small molecule Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
APREMILAST, (±)- is a mixture of isomers, one of them is therapeutic active S form (apremilast), an inhibitor of phosphodiesterase 4. This active form is sold under the brand name OTEZLA for the treatment of adult patients with active psoriatic arthritis.   NCATS

Chemistry

  • SMILES: CCOC1=C(OC)C=CC(=C1)C(CS(C)(=O)=O)N2C(=O)C3=C(C2=O)C(NC(C)=O)=CC=C3
  • InChIKey: IMOZEMNVLZVGJZ-UHFFFAOYSA-N
  • Mol. Mass: 460.5
  • ALogP: 2.43
  • ChEMBL Molecule:
    apremilast  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$8.5140

United States

$41.2063 - $62.3862
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

apremilast | aprémilast | apremilastum | cc-100004 | cc10004 | cc 10004 | cc-10004 | n-{2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1h-isoindol-4-yl}acetamide | otezla

Organizations (106)

Research & Development (95)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (40)

Approved Indications (2)


 

Arthritis, Psoriatic

Psoriasis

Experimental Indications - Clinical Trial Phases 1-4 (40)


 

Acne Conglobata (Phase 2)

Acne Vulgaris (Phase 2)

Alcoholism (Phase 2)

Alopecia (Phase 4)

Arthritis, Psoriatic ()

Arthritis, Rheumatoid (Phase 2)

Behcet Syndrome (Phase 3)

Cardiovascular Diseases (Phase 4)

Colitis, Ulcerative (Phase 2)

COVID-19 (Phase 3)

Dermatitis, Allergic Contact (Phase 2)

Dermatitis, Atopic (Phase 2)

Dermatology (Phase 2)

Dermatomyositis (Phase 2)

Digital Dermatitis (Phase 4)

Eczema (Phase 2)

Erythema (Phase 4)

Genital Diseases, Female (Phase 2)

Gout (Phase 2)

Healthy Volunteers (Phase 1)

Hidradenitis Suppurativa (Phase 2)

Lichen Planus (Phase 2)

Lichen Planus, Oral (Phase 2)

Lupus Erythematosus, Discoid (Phase 1/Phase 2)

Osteoarthritis (Phase 2)

Parapsoriasis (Phase 4)

Pharmacokinetics (Phase 1)

Prostatitis (Phase 2)

Prurigo (Phase 2)

Pruritus (Phase 2)

Psoriasis ()

Rosacea (Phase 2)

Sarcoidosis (Phase 2/Phase 3)

Spondylitis, Ankylosing (Phase 3)

Stomatitis, Aphthous (Phase 3)

Substance Withdrawal Syndrome (Phase 3)

Uveitis (Phase 1/Phase 2)

Vitiligo (Phase 2)

Vulva (Phase 2)

Vulvodynia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 114
  • # of Trial Organizations: 95

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue